Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market - Longeveron (NASDAQ:LGVN), Amgen (NASDAQ:AMGN)

Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat.

Related Keywords

Miami ,Florida ,United States ,Greg Olsen ,Sunjay Kaushal ,Food Drug Administration ,Survival Rate For Phase ,Principal Investigator ,Orphan Drug Designation ,Rare Pediatric Designation Longeveron ,Drug Administration ,Carlo Navarro ,